Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies
Abstract Background Vaccination against Coronavirus disease 2019 (COVID-19) is an important means of controlling the pandemic, however they are expected to stimulate immune responses when administered to confer immunity. In this review, we evaluated the clinical and laboratory features associated wi...
Saved in:
Main Authors: | Chinonyerem O. Iheanacho (Author), Uchenna I. H. Eze (Author) |
---|---|
Format: | Book |
Published: |
SpringerOpen,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination
by: Jaeeun Yoo, et al.
Published: (2023) -
Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
by: Francesca Fortunato, et al.
Published: (2023) -
Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England
by: Nick J Andrews, et al.
Published: (2022) -
Psoriatic flare following Oxford-AstraZeneca ChAdOx1 COVID-19 and influenza vaccines
by: Natalie Teh, et al.
Published: (2021) -
Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses
by: Diana Lourdes Padilla-Bórquez, et al.
Published: (2024)